Health and Me on MSN
Fatty liver disease: Scientists identify 5 subtypes with different health risks
Researchers also identified associations between specific subtypes and conditions such as depression, sleep apnea and ...
In its own approval announcement on Oct. 20, the FDA hailed Hibsago as a “first-of-its-kind” treatment in chronic hepatitis B ...
"Research has shown that being inactive is one of the strongest predictors of disease progression and early death. That may ...
YAQ001 associated with favorable shifts in gut microbial species and lower abundance of virulence and antibiotic resistance genesTrends toward ...
The mechanisms that cause the world's most common chronic liver disease—metabolic dysfunction-associated steatotic liver ...
For the first time, many people living with chronic hepatitis B may have a functional cure at hand. The US Food and Drug ...
A new study led by investigators from Mass General Brigham found routine liver cancer screening to be cost-effective and life ...
New weight-loss drugs and bariatric surgery are crucial for obesity treatment, enhancing metabolic health and aiding ...
Some adults with chronic hepatitis B may now have a path to something today's treatments rarely deliver—stopping all ...
A rare inherited change in a single gene may directly cause fatty liver disease in some people, even when they lack familiar ...
Mens Fitness on MSN
FDA Approves Hibsago, a Hepatitis B Treatment That Could Let Some Patients Stop Therapy
FDA-approved Hibsago could help some adults with chronic hepatitis B stop antiviral therapy. Learn who qualifies, what trials found, and the key risks.
FDA approves Hibsago (bepirovirsen) with NrtI therapy for adult chronic hepatitis B without cirrhosis; phase 3 trials show up to 20% functional cure at 72 weeks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results